Filing Flows › Lineage Cell Therapeutics (LCTX) › Recalls, complaints & regulation
Lineage Cell Therapeutics (LCTX): clinical trials
Lineage Cell Therapeutics (LCTX) beyond its filings: 3 active clinical trials.
Lineage Cell Therapeutics' latest quarter
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Lineage Cell Therapeutics have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.